Alla Danilkovitch, Ph.D.

Back to Leadership

Chief Scientific Officer


Alla Danilkovitch joined Osiris in 2003. Dr. Danilkovitch has a proven record of successful product development from scientific ideas to market launch, which includes the world’s first approved stem cell drug, remestemcel-L, for graft-versus-host disease as well as BIO4® for bone repair, Cartiform® for cartilage repair, and Grafix® for acute and chronic wounds. Prior to joining Osiris, Dr. Danilkovitch conducted research at the National Cancer Institute of National Institutes of Health, the Max Planck Institute of Biochemistry in Munich, and at Moscow State University. Dr. Danilkovitch earned a Ph.D. in cell biology and an M.S. in cellular immunology and microbiology from Moscow State University.

Alla Danilkovitch